Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2006

View Archived Issues

AstraZeneca completes Cambridge Antibody Technology acquisition

SPA for second pivotal study of TH-9507 in HIV-associated lipodystrophy

Negative outcomes for first phase III study of Corlux in psychotic major depression

CUV-1647 meets endpoints in polymorphous light eruption study

Probactrix studied for dietary management of GERD

Enrollment completed in study of Ketasyn for age associated memory impairment

Devgen compounds may show promise for rheumatoid arthritis

LCT seeks approval to begin phase I/II diabetes study of DiabeCell in patients

ChronVac-C with Medpulser DDS shows good immune response in rabbits

Switch Pharma to acquire Gardant

Biotransformation of a novel delta/mu opioid receptor agonist with promising analgesic potential

New therapeutic agents for psoriasis disclosed in recent Nippon Shinyaku patent

Lilly reports on a novel class of positive allosteric modulators of AMPA receptors

AzaSite NDA accepted for review

Orapred ODT launched in U.S.

FDA denies Epix's formal appeal for Vasovist

First European approval for Lucentis in Switzerland

Apnecut launched in Japan for apnea of prematurity

Rotigotine transdermal patch enables rapid titration in Parkinson's disease patients

Novel agents for urological disorders disclosed in recent Dainippon Sumitomo patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...